AbCellera to Present Cutting-Edge T-Cell Engager Discovery Findings at AACR 2023
March 17, 2023
Trending News ☀️
ABCELLERA ($NASDAQ:ABCL): AbCellera Biologics will be presenting cutting-edge findings on their T-Cell Engager discovery at the upcoming AACR 2023 meeting. The talks will cover two different aspects of the discovery, providing insight into how AbCellera is helping to revolutionize cancer treatment. The first talk will discuss how AbCellera’s proprietary technologies allow them to rapidly identify potential T-Cell Engagers from patient samples. This is not only important for drug discovery, but it also helps to identify new therapeutic targets for immunotherapy.
The second talk will focus on how AbCellera has used their proprietary technologies to develop a library of thousands of T-Cell Engagers that can be used to facilitate cancer immunotherapy. By combining multiple T-Cell Engagers, researchers are able to improve the efficacy of their treatments. With these talks, AbCellera hopes to demonstrate the value of their technologies and how they are revolutionizing cancer treatment.
Stock Price
This news has brought some positive attention to the company as their stock opened on Tuesday at $7.6 and closed at the same price, up 2.0% from the prior closing price of $7.4. These findings could lead to groundbreaking new treatments for cancer and other diseases, broadening their drug discovery capabilities and furthering their mission to develop the most effective therapies available. AbCellera Biologics is committed to revolutionizing the way treatments are developed and bringing hope to those suffering from serious and life-threatening illnesses. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Abcellera Biologics. More…
| Total Revenues | Net Income | Net Margin |
| 485.42 | 158.52 | 32.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Abcellera Biologics. More…
| Operations | Investing | Financing |
| 277.36 | -352.62 | -1.63 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Abcellera Biologics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.54k | 307.63 | 4.3 |
Key Ratios Snapshot
Some of the financial key ratios for Abcellera Biologics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 247.1% | 541.4% | 50.1% |
| FCF Margin | ROE | ROA |
| 42.2% | 12.2% | 9.9% |
Analysis
At GoodWhale, we recently conducted an analysis of ABCELLERA BIOLOGICS‘s wellbeing. After careful review of the company’s financial and business aspects, our Risk Rating score classifies ABCELLERA BIOLOGICS as a high risk investment. We have identified three risk warnings in the income sheet, balance sheet, and cashflow statement of ABCELLERA BIOLOGICS. These warnings can act as important indicators to prospective investors, allowing them to make informed decisions about their investments. To gain a comprehensive understanding of the risks associated with ABCELLERA BIOLOGICS, we recommend that you become a registered user to access our detailed analysis. More…
Peers
Its mAbs target CD3, CD20, HER2, EGFR and other proteins. AbCellera has partnerships with Pfizer, Merck, Eli Lilly, Genentech, Janssen, Novartis, Seattle Genetics and others. The company was founded in 2012 and is headquartered in Vancouver, Canada. Ensysce Biosciences Inc is a biopharmaceutical company that focuses on the development of immuno-oncology therapeutics. Its products include ENS-761, ENS-784 and ENS-861. The company was founded in 2007 and is headquartered in La Jolla, CA. INmune Bio Inc is a clinical-stage biopharmaceutical company that develops treatments for cancer and other diseases. Its products include INK-128, INK-185 and INB-1008. The company was founded in 2015 and is headquartered in La Jolla, CA. Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company that develops immuno-oncology therapeutics. Its products include SON-101, SON-201 and SON-301. The company was founded in 2016 and is headquartered in New York, NY.
– Ensysce Biosciences Inc ($NASDAQ:ENSC)
Ensysce Biosciences Inc is a clinical stage biopharmaceutical company. The Company focuses on developing therapies for patients with cancer and other serious diseases. Ensysce’s proprietary technology is based on stabilizing drugs in their active form, which allows for safe and effective administration to patients. The Company’s lead product candidate is EBC-46, which is in Phase I/II clinical trials for the treatment of head and neck cancer.
– INmune Bio Inc ($NASDAQ:INMB)
Innate Immunotherapeutics is a clinical-stage biotechnology company developing medicines to treat autoimmune and inflammatory diseases. The company has a market cap of $126.88M as of 2022 and a Return on Equity of -27.44%. Innate Immunotherapeutics is focused on the development of treatments for patients with severe autoimmune and inflammatory diseases who have limited or no treatment options. The company’s lead product candidate, IPL512,602, is a monoclonal antibody that is being developed for the treatment of patients with severe autoimmune and inflammatory diseases.
– Sonnet BioTherapeutics Holdings Inc ($NASDAQ:SONN)
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of novel, small molecule therapeutics for the treatment of cancer. The company’s product pipeline includes SNT-100, SNT-101, and SNT-102. Sonnet BioTherapeutics Holdings Inc was founded by Jonathan Goldman and David A. Goldman in 2015 and is headquartered in New York, NY.
Summary
ABCELLERA Biologics has been making a mark on the biotechnology industry with its cutting-edge T-Cell Engager discovery findings, which are set to be presented at AACR 2023. Analysts are optimistic about investing in the company due to its innovative approach to drug discovery and development, and its broadened product pipeline. ABCELLERA is currently working on advancing its lead product candidates for cancer and autoimmune diseases. The company’s strong IP portfolio and collaborations with leading pharmaceutical companies position it as a strong contender in this field.
Additionally, the company continues to expand its strategic partnerships and explore new opportunities in the immuno-oncology space. Investors are expecting ABCELLERA’s share price to continue increasing as its discoveries are further validated.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
